Compare GNE & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNE | RZLT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 471.0M |
| IPO Year | 2011 | 2011 |
| Metric | GNE | RZLT |
|---|---|---|
| Price | $16.66 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 50.1K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 95.65 | 23.47 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $425,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.86 | $2,214.20 |
| P/E Ratio | $30.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.69 | $1.07 |
| 52 Week High | $17.11 | $11.46 |
| Indicator | GNE | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 49.75 |
| Support Level | $15.80 | $3.69 |
| Resistance Level | $16.89 | $5.36 |
| Average True Range (ATR) | 0.49 | 0.27 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 54.77 | 73.44 |
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.